Merck’s President of Global Human Health Adam H. Schechter to Leave Merck Frank Clyburn Named Chief Commercial Officer and Michael Nally Named Chief Marketing Officer


December 10, 2018 4:30 pm ET

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that Adam H. Schechter, president of Global Human Health
(GHH), is stepping down from his current position as of Dec. 31, 2018,
and will be shifting to an advisory capacity to the CEO. The company is
taking the opportunity to reshape its commercial organization and is
creating two new Executive Committee roles. Frank Clyburn has been
promoted to Chief Commercial Officer and Michael Nally has been promoted
to Chief Marketing Officer.

Schechter has been the president of GHH since 2010. He joined the
company in 1988. Schechter has been responsible for the performance of
our human health business during a period of significant change, and
also evolved Merck’s commercial organization to strengthen the company’s
ability to bring its medicines and vaccines to people in more than 140
countries around the world. In addition to his accomplishments in
Merck’s commercial organization throughout his 30-year career, Schechter
led the integration of Merck and Schering-Plough, a significant
milestone in the creation of today’s Merck.

“Adam’s leadership and unwavering dedication to finding new ways to
bring Merck’s medicines and vaccines to more patients around the world
have been hallmarks of his time at Merck. I have relied on his
experience and expertise as we evolved a world-class commercial
organization, spanning primary care, hospital and specialty, vaccines
and oncology,” said Kenneth C. Frazier, Chairman and Chief Executive
Officer, Merck. “Because of him we are better positioned to address
future opportunities and challenges as a global biopharmaceutical
company, and Frank and Mike have a great foundation upon which to build
future success.”

“It has been my honor to be a part of Merck for 30 years and to lead
Global Human Health since 2010,” Schechter said. “I am proud of how we
have transformed our business and have been able to ensure that Merck’s
remarkable medicines and vaccines are available to so many people around
the world. I know that Frank and Mike share that passion for achieving
Merck’s mission, and I am confident that they will build on GHH’s track
record of driving growth and continue the momentum we have across our
global business today.”

Frank Clyburn, who will take on the role of Chief Commercial Officer,
effective Jan. 1, 2019, has held a number of leadership positions across
Merck. Most recently, Clyburn was the President of the Global Oncology
business. In his new role, Clyburn will report directly to Ken Frazier
and will be a member of the Executive Committee. He will be responsible
for all operations and P&L across Merck’s human health commercial
portfolio globally. Clyburn joined Merck in 2008 and has had
responsibility for numerous global pharmaceutical franchises, including
diabetes, cardiovascular and women’s health, as well as leadership of
marketing and sales teams.

Michael Nally, who will become Chief Marketing Officer, effective Jan.
1, 2019, most recently led the company’s Vaccines business. In his new
role, Nally will report directly to Ken Frazier and will be a member of
the Executive Committee. Nally will be responsible for Global Marketing
and long-term franchise strategy across the portfolio. Nally has been at
Merck since 2003 and served in a number of roles with responsibilities
including being the Managing Director of UK, Ireland and Sweden as well
a variety of roles in Commercial Operations, Business Development and
Investor Relations.

About Merck

For more than a century, Merck, a leading global biopharmaceutical
company known as MSD outside of the United States and Canada, has been
inventing for life, bringing forward medicines and vaccines for many of
the world’s most challenging diseases. Through our prescription
medicines, vaccines, biologic therapies and animal health products, we
work with customers and operate in more than 140 countries to deliver
innovative health solutions. We also demonstrate our commitment to
increasing access to health care through far-reaching policies, programs
and partnerships. Today, Merck continues to be at the forefront of
research to advance the prevention and treatment of diseases that
threaten people and communities around the world – including cancer,
cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease
and infectious diseases including HIV and Ebola. For more information,
visit and connect
with us on Twitter,
and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the
“company”) includes “forward-looking statements” within the meaning of
the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs
and expectations of the company’s management and are subject to
significant risks and uncertainties. If underlying assumptions prove
inaccurate or risks or uncertainties materialize, actual results may
differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties
or delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of the company’s patents
and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results
to differ materially from those described in the forward-looking
statements can be found in the company’s 2017 Annual Report on Form 10-K
and the company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (

Media Contacts:
Pam Eisele, (267) 305-3558
Jennifer Mauer, (908) 740-1808

Investor Contacts:
Peter Dannenbaum, (908) 740-1037
Teri Loxam, (908) 740-1986

Unsubscribe from email alerts